Azacitidine, Venetoclax, and Gilteritinib

A Phase I/II Study of Azacitidine, Venetoclax, and Gilteritinib for Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome With an Activating FLT3 Mutation

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1/2
Enrollment
97 patients (estimated)
Sponsors
MD Anderson Cancer Center
Tags
Antimetabolites, BCL-2 Inhibitor, Hypomethylating Agents (HMA), Tyrosine Kinase (TK) Inhibitor
Trial Type
Treatment
Last Update
4 weeks ago
SparkCures ID
1550
NCT Identifier
NCT04140487

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.